-
Esperion is being closed and its 70 employees will lose their jobs or move to other Pfizer labs.
FORBES: Magazine Article
-
In the past year Pfizer has closed six labs, including the Michigan outpost where Lipitor was invented.
FORBES: Drug Drought
-
Pfizer acquired Brazilian generic labs Teuto last year.
FORBES: Dr. Reddy's Opens NYSE; CEO Says Will Move into Branded Drugs
-
Today, at Pfizer's research presentation at its labs in Groton, Conn.
FORBES: Magazine Article
-
Never mind that a bidding war will inevitably result in an overpriced Biogen--current Pfizer shareholders might do just as well if Pfizer delivers a few upside surprises from its own labs.
FORBES: Should Pfizer Buy Biogen? No.
-
He said Pfizer had left behind a large amount of fixed equipment in the labs.
BBC: Pfizer site: New owner hopes for 3,000 new jobs
-
Pfizer has seen its stock under-perform some of its peers like Abbott Labs and Merck as the company continues to struggle with various lawsuits and complaints.
FORBES: Pfizer Is Worth $25 Despite Lawsuits And Lipitor Patent Expiry
-
In the future, Pfizer hopes to be launching six products a year--including four developed in its own labs.
FORBES: At Pfizer, Brutal Cuts And Big Changes
-
Pfizer is just coming off of a big effort to pare its research effort, creating more organized labs.
FORBES: Should Pfizer Buy Biogen? No.
-
Helped by recent news of a weak economy and record low interest rates, the stocks of major pharmaceutical companies like Abbott Labs (NYSE:ABT), Lilly Eli (NYSE:LLY), Pfizer (NYSE:PFE), Merck (NYSE:MRK), and Bristol Myers Squibb traded near 52-week highs this morning.
FORBES: Pharmaceuticals Trading Near 52-Week Highs
-
Today, at Pfizer's (nyse: PFE - news - people ) research presentation at its labs in Groton, Conn.
FORBES: Pfizer: Still In The Game
-
In the past four years, AstraZeneca ( AZN), Pfizer ( PFE), Eli Lilly ( LLY), Bristol-Myers Squibb ( BMY) and Forest Labs ( FRX) have all settled federal charges of marketing psychoactive drugs off-label, at a cost running into hundreds of millions.
FORBES: Bad Side-Effects Ahead For Pharma?